Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma

Malignant mesothelioma is a highly aggressive tumor with a survival of only 4-18 months after diagnosis. Treatment options for this disease are limited. Immune checkpoint blockade using ipilimumab and nivolumab has recently been approved as a frontline therapy, but this led to only a small improveme...

Celý popis

Podrobná bibliografie

Vydáno v:	Cancer research communications Ročník 4; číslo 1; s. 18 - 27
Hlavní autoři:	Badhai, Jitendra, Landman, Nick, Pandey, Gaurav Kumar, Song, Ji-Ying, Hulsman, Danielle, Krijgsman, Oscar, Chandrasekaran, Gayathri, Berns, Anton, van Lohuizen, Maarten
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States American Association for Cancer Research 03.01.2024
Témata:	Animals Biomarkers Enhancer of Zeste Homolog 2 Protein - genetics Humans Lung Cancer Lung Neoplasms - drug therapy Melanoma - drug therapy Mesothelioma - drug therapy Mesothelioma, Malignant Mice Preclinical Models Small Molecule Agents Translational Research Tumor Suppressor Proteins - genetics Ubiquitin Thiolesterase - genetics
ISSN:	2767-9764, 2767-9764
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!